A switch from CD44+ cell to EMT cell drives the metastasis of prostate cancer

Oncotarget

Volumn 6, Issue 2, 2015, Pages 1202-1216

  Shang, Zhiqun ^a   Cai, Qiliang ^a   Zhang, Minghao ^a   Zhu, Shimiao ^a   Ma, Yuan ^a   Sun, Libin ^a   Jiang, Ning ^a   Tian, Jing ^a   Niu, Xiaodan ^b   Chen, Jiatong ^c   Sun, Yinghao ^d   Niu, Yuanjie ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER   (United States)

^c NANKAI UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Androgen deprivation therapy; Cancer stem cell; CD44; Epithelial mesenchymal transition; Prostate cancer; TGF 1

Indexed keywords

ANDROGEN RECEPTOR; HERMES ANTIGEN; NERVE CELL ADHESION MOLECULE; SALINOMYCIN; SMALL INTERFERING RNA; UVOMORULIN; VIMENTIN; ANTIANDROGEN; CADHERIN; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER STEM CELL LIKE CELL; CASTRATION; CONTROLLED STUDY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATECTOMY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CANCER STEM CELL; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; NUDE MOUSE; ORCHIECTOMY; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANDROGEN ANTAGONISTS; ANIMALS; ANTIGENS, CD44; BLOTTING, WESTERN; CADHERINS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICE, INBRED BALB C; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921785029     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2841     Document Type: Article

References (46)

1. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939.
2. Khan MI1, Adhami VM, Lall RK, Sechi M, Joshi DC, Haidar OM, Syed DN, Siddiqui IA, Chiu SY, Mukhtar H.YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin. Oncotarget. 2014 May 15;5(9):2462-74.
3. Brabletz, T., Jung, A., Spaderna, S., Hlubek, F., Kirchner, T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5(9): 744-749.
4. Dalerba, P., Cho, R.W., Clarke, M.F. Cancer stem cells: models and concepts. Annu Rev Med 2007; 58:267-284.
5. Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I, Nieto MA. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004; 18:1131-1143.
6. Mejlvang J, Kriajevska M, Vandewalle C, Chernova T, Sayan AE, Berx G, Mellon JK, Tulchinsky E. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell 2007; 18:4615-4624.
7. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-715.
8. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008; 3: e2888.
9. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R, Kirchner T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001; 98(18):10356-10361.
10. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res.2006; 66(23):11271-11278.
11. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011; 17(9):1101-1108.
12. Tsai, J.H., Donaher, J.L., Murphy, D.A., Chau, S., Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012; 22(6),725-736.
13. Ocaña OH, Córcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell. 2012; 22(6),709-724.
14. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254-267.
15. Clevers, H. The cancer stem cell: premises, promises and challenges. Nat Med 2011; 17: 313-319.
16. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST. Significance of CD90 cancer stem cells in human liver cancer. Cancer Cell 2008; 13:153-166.
17. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-3988.
18. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104:973-978.
19. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, et al. Identification of miR-34a as a potent inhibitor of prostate cancer progenitor cells and metastasis by directly repressing CD44. Nat Med 2011; 17(2), 211-215.
20. Li L, Liu C, Amato RJ, Chang JT, Du G, Li W. CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. Oncotarget. 2014 Oct 15. [Epub ahead of print].
21. Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, Watanabe M, Beppu T, Tamada M, Nagano O, Saya H, Baba H. CD44s Regulates the TGF-b-Mediated Mesenchymal. Phenotype and Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Res 2012; 72:3414-3423.
22. Oshimori, N., Fuchs, E. Naoki Oshimori and Elaine Fuchs. The Harmonies Played by TGF-b in Stem Cell Biology. Cell Stem Cell 2012; 11(6): 751-764.
23. Lin TH1, Lee SO, Niu Y, Xu D, Liang L, Li L, Yeh SD, Fujimoto N, Yeh S, Chang C. Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide versus Anti-androgen Receptor ASC-J9 Lead to Promotion versus Suppression of Prostate Cancer Metastasis. J. Biol. Chem. 2013; 288:19359-19369.
24. Fuzio P, Ditonno P, Rutigliano M, Battaglia M, Bettocchi C, Loverre A, Grandaliano G, Perlino E. Regulation of TGF-b1 expression by Androgen Deprivation Therapy of prostate cancer. Cancer Letters 2012; 318:135-144.
25. Feldman, B.J. and Feldman, D. The development of androgen independent prostate cancer. Nat Rev Cancer 2011; 1:34-45.
26. Montironi, R., Mazzucchelli, R., Lopez-Beltran, A., Cheng, L., Scarpelli, M. Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat. Clin. Pract. Urol 2007; 4(6):321-332.
27. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL, Weinberg RA. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011; 145:926-940.
28. Tata PR, Mou H, Pardo-Saganta A, Zhao R, Prabhu M, Law BM, Vinarsky V, Cho JL, Breton S, Sahay A, Medoff BD, Rajagopal J. Dedifferentiation of committed epithelial cells into stem cells in vivo. Nature 2013; 503(7475): 218-223.
29. Goldstein A.S., Huang J., Guo C., Garraway I.P., Witte O.N. Identification of a cell of origin for human prostate cancer. Science. 2010; 329(5991): 568-571.
30. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105(34):12182-12187.
31. Brigham C., Willis1., Zea B. TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007; 293:525-534.
32. Gu X, Zerbini LF, Otu HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, Libermann TA. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 2007; 67:4219-4226.
33. Findlay VJ, Turner DP, Yordy JS, McCarragher B, Shriver MR, Szalai G, Watson PM, Larue AC, Moussa O, Watson DK. Prostate-Derived ETS Factor Regulates Epithelial-to-Mesenchymal Transition through Both SLUG-Dependent and Independent Mechanisms. Genes Cancer. 2011 Feb;2(2):120-9.
34. Bernardo MM, Meng Y, Lockett J, Dyson G, Dombkowski A, Kaplun A, Li X, Yin S, Dzinic S, Olive M, Dean I, Krass D, Moin K, Bonfil RD, Cher M, Sakr W, Sheng S. Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer. 2011 Nov; 2(11):1009-22.
35. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25:1696-1708.
36. Zhang GN, Liang Y, Zhou LJ, Chen SP, Chen G, Zhang TP, Kang T, Zhao YP. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells, Cancer Letters 2011; 313(2): 137-144.
37. Zhang Y, Zhang H, Wang X, Wang J, Zhang X, Zhang Q. The eradication of breast cancer and cancer stem cells using octreotide modifified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 2012; 33(2):679-691.
38. Gupta, P.B., et al. Identifification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138(4):645-659.
39. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas, Cell Cycle 2010; 10(12): 2008-2016.
40. Fuchs, D., Heinold, A., Opelz, G., Daniel, V., and Naujokat, C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochemical and Biophysical Research Communications 2009; 390(3):743-749.
41. Kim WK, Kim JH, Yoon K, Kim S, Ro J, Kang HS, Yoon S. Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Investigational New Drugs 2011; 30:1311-1318.
42. Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, Han R, Ma T, Kuo HC, Chang C. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res. 2008, 68:7110-7119.
43. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL, Weinberg RA. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926-940.
44. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011,59:572-583.
45. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011, 59:61-71.
46. Ekici S., Ayhan, A., Kendi, S., Ozen, H. Determination of prognosis in patients with prostate cancer treated with radical prostatectomy: prognostic value of CD44v6 score. J Urol. 2002, 167:2037-2041.